Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1128

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1128
---
 development and use of AI, including generative AI, could result in competitive harm, reputational harm, and legal liability, and adversely affect our results of operations.

    ●
    We have limited corporate infrastructure and may experience difficulties in managing growth.

    ●
    We have experienced and may continue to experience significant turnover in our management and executive leadership, which creates uncertainty and could harm our ability to operate our business effectively.

19

    ●
    
    If serious adverse events or other undesirable
side effects or safety concerns attributable to our product candidates occur, they may adversely affect or delay our clinical development
and commercialization of some or all of our product candidates.

    ●
    Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance.

    ●
    Sales of a substantial number of shares of our Common Stock in the public market could cause our stock price to fall.

    ●
    Future sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

Investing in our Common Stock involves a high degree
of risk. Investors should carefully consider all of the risk factors and uncertainties described below, in addition to the other information
contained in this Annual Report on Form 10-K, including the section of this report titled “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” and our consolidated financial statements and related notes, before investing
in our Common Stock. 

The risks described below may not be the only ones
relating to our Company and additional risks that we currently believe are immaterial may also affect us. If any of these risks, including
those described below, materialize, our business, competitive position, reputation, financial condition, results of operations, cash flows
and future prospects could be seriously harmed. In these circumstances, the market price of our Common Stock could decline, and investors
may lose all or a part of their investment.

Risks Related to Our Financial Position and Capital
Requirements

We have incurred substantial
losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.

Lunai is a pre-clinical-stage
biotechnology company and AI-driven healthcare technology company. Investment in biotechnology related to genetically modified cells is
highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail